

Miguel Escobar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3805320/publications.pdf>

Version: 2024-02-01

22
papers

338
citations

933447

10
h-index

839539

18
g-index

22
all docs

22
docs citations

22
times ranked

350
citing authors

#	ARTICLE	IF	CITATIONS
1	Recommendations on multidisciplinary management of elective surgery in people with haemophilia. Haemophilia, 2018, 24, 693-702.	2.1	60
2	Health economics in haemophilia: a review from the clinician's perspective. Haemophilia, 2010, 16, 29-34.	2.1	39
3	Low-factor consumption for major surgery in haemophilia B with long-acting recombinant glycoPEGylated factor IX. Haemophilia, 2017, 23, 67-76.	2.1	31
4	Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8â€GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial). Haemophilia, 2019, 25, 373-381.	2.1	29
5	Multidisciplinary management of patients with haemophilia with inhibitors undergoing surgery in the United States: perspectives and best practices derived from experienced treatment centres. Haemophilia, 2012, 18, 971-981.	2.1	28
6	Integrated Hemophilia Patient Care via a National Network of Care Centers in the United States: A Model for Rare Coagulation Disorders. Journal of Blood Medicine, 2021, Volume 12, 897-911.	1.7	21
7	Advances in the treatment of inherited coagulation disorders. Haemophilia, 2013, 19, 648-659.	2.1	19
8	Treatment on demand -in vivo dose finding studies. Haemophilia, 2003, 9, 360-367.	2.1	14
9	Switching patients in the age of long-acting recombinant products?. Expert Review of Hematology, 2019, 12, 1-13.	2.2	14
10	Postoperative bleeding complications in patients with hemophilia undergoing major orthopedic surgery: A prospective multicenter observational study. Journal of Thrombosis and Haemostasis, 2022, 20, 857-865.	3.8	14
11	Real-world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years. Haemophilia, 2020, 26, 975-983.	2.1	12
12	Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results. Blood, 2022, 140, 89-98.	1.4	12
13	The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors. Haemophilia, 2021, 27, 921-931.	2.1	7
14	Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (Tj ETQq0 0,0 rgBT /Overlock 10 T	2.1	7
15	Optimal trough levels in haemophilia B: Raising expectations. Haemophilia, 2020, 26, e334-e336.	2.1	6
16	IDELVION: A Comprehensive Review of Clinical Trial and Real-World Data. Journal of Clinical Medicine, 2022, 11, 1071.	2.4	6
17	A phase IV, multicentre, open-label study of emicizumab prophylaxis in people with haemophilia A with or without FVIII inhibitors undergoing minor surgical procedures. Haemophilia, 2022, 28, .	2.1	6
18	PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant) Tj ETQq0 0 0 rgBT /Overlock 10 T	2.1	5

#	ARTICLE	IF	CITATIONS
19	Utilization patterns and associated costs of factor assistance programmes among persons with haemophilia: a single institution review. <i>Haemophilia</i> , 2012, 18, e95-e100.	2.1	3
20	World federation of hemophilia international hemophilia training fellowship program: 50 years of enhancing global care. <i>Haemophilia</i> , 2022, 28, .	2.1	3
21	Immune tolerance induction with antihemophilia factor (human) in poor prognosis patients with haemophilia A. <i>Haemophilia</i> , 2021, 27, e393-e397.	2.1	2
22	<p>Efficacy of EHL N9-GP for on-demand treatment of bleeding episodes in hemophilia B: analysis of pivotal trial data</p>. <i>Journal of Blood Medicine</i> , 2019, Volume 10, 243-250.	1.7	0